Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

This study is testing QLS32015, a new drug combination therapy, in patients with multiple myeloma (a bone marrow cancer) that has come back or stopped responding to at least one prior treatment, to evaluate its effectiveness and safety. **You may be eligible if...** - You have a confirmed diagnosis of multiple myeloma - Your disease has relapsed or progressed after at least one prior treatment - You have measurable disease detectable through blood or urine tests **You may NOT be eligible if...** - You have previously experienced a severe (grade 3 or higher) cytokine release syndrome from T-cell redirecting therapies or CAR-T cell therapy - You have received GPRC5D-targeted therapy previously - You have received CAR-T cell therapy in the past 3 months - You received other myeloma treatments (monoclonal antibodies, chemotherapy, etc.) within specified timeframes before enrollment - You cannot tolerate the drug components based on prior serious reactions Talk to your doctor to see if this trial is right for you.